"label","instanceType","uuid:ID","name","id","description","text"
"","Objective","3c962412-e503-496e-adbf-5b2e718cefdf","OBJ1","Objective_1","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"","Objective","2af8d100-491d-418a-8671-c2fa03b12a9f","OBJ2","Objective_2","Safety","To document the safety profile of the xanomeline TTS."
"","Objective","aeb37100-a27f-4fd6-ac03-a91b2bd6b492","OBJ3","Objective_3","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"","Objective","0c36f388-adf3-40f2-9a3c-42d4bbd2df34","OBJ4","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"","Objective","9012105b-dcbc-4e0a-b828-46fce1800ab0","OBJ5","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"","Objective","a822bfa7-c3f5-4bb6-9b85-ef725a590223","OBJ6","Objective_6","","To assess the treatment response as a function of Apo E genotype."
